Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Viatris Inc chart...

About the Company

mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.

CEO

Michael Goettler

Exchange

NASDAQ

Website

mylan.com

$15B

Total Revenue

12K

Employees

$14B

Market Capitalization

13.18

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $VTRS News

3 High-Potential S&P 500 Healthcare Stocks Offering 30%+ Upside

on MSN ago, source:

After a sluggish 2023, 2024 looks brighter for healthcare stocks. Numerous demographic and social factors also argue in favor ...

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline

1d ago, source:

At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its R&D strategy to deliver on its goal of ...

Is Viatris a Great Dividend Stock or Just a Value Trap?

on MSN ago, source:

On an annual basis, Viatris spends about $580 million on its dividend payments. That suggests that its current dividend is ...

Viatris generic hypertension drug does not violate J&J patents, US court says

13d ago, source:

Generic drugmaker Viatris has convinced a federal judge in West Virginia that its proposed generic version of a Johnson & ...

11 Undervalued Stocks for Less Than $50 in March 2024

on MSN ago, source:

These inexpensive and undervalued stocks are top performers with strong upside potential based on the company’s price-to-book ...

Ford, Envista Holdings, and Alaska Air are among additions to GS’ Short Duration list

on MSN ago, source:

Goldman Sachs analysts published their rebalanced list for their “short duration” basket, with additions such as Ford (F), ...

GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration

11mon ago, source:

LR Allschwil, Switzerland - March 18, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the ...

Viatris: Inclusion, Belonging, and the Making of a Role Model

16d ago, source:

Niki KapsambelisWhen Lauren Kashtan thinks about the point in her life when she started to realize what she stood for, she zeroes in on middle ...

Russell 1000 stocks with secured dividends that are not stretched - BofA

14d ago, source: Seeking Alpha

BofA analysts published a screen with Russell 1000 (NYSEARCA:IWF) stocks with secure dividends that are not stretched. In a ...

Teva stock trades in the green for seventh straight session

1d ago, source:

Teva Pharmaceutical ( NYSE: TEVA) shares traded in the green on Wednesday, making it the seventh straight day of gains. Stock ...

Viatris' Indore Site Receives International Sustainability Rating System Certification

2d ago, source:

NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Viatris' Indore manufacturing site has received certification for International Sustainability Rating System (ISRS), 9th Edition - Process Safety, from ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...